nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.10.2017 | Systematic Review

Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review

verfasst von: Till Weidner, Tanja Illing, Peter Elsner

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Primary localized cutaneous amyloidosis (PLCA) is characterized by extracellular deposition of heterogenic amyloid proteins in the skin without systemic involvement. Lichen amyloidosis, macular amyloidosis, and (primary localized cutaneous) nodular amyloidosis are different subtypes of PLCA.

Objective

The aim of this study was to review the current reported treatment options for PLCA.

Methods

This systematic review was based on a search in the PubMed database for English and German articles from 1985 to 2016.

Results

Reports on the treatment of PLCA were limited predominantly to case reports or small case series. There were a few clinical trials but these lacked control groups. A variety of treatment options for PLCA were reported including retinoids, corticosteroids, cyclophosphamide, cyclosporine, amitriptyline, colchicine, cepharanthin, tacrolimus, dimethyl sulfoxide, vitamin D₃ analogs, capsaicin, menthol, hydrocolloid dressings, surgical modalities, laser treatment, and phototherapy.

Conclusion

No definitive recommendation of preferable treatment procedures can be made based on the analyzed literature. Randomized controlled trials are needed to offer patients an evidence-based therapy with high-quality standardized treatment regimens for PLCA.

Fernandez-Flores A. Cutaneous amyloidosis: a concept review. Am J Dermatopathol. 2012;34(1):1–14 (quiz 5–7). doi:10.1097/DAD.0b013e31823465c7.

Brownstein MH, Hashimoto K, Greenwald G. Biphasic amyloidosis: link between macular and lichenoid forms. Arch Dermatol. 1972;106(3):419.PubMed

Ollague W. Primary cutaneous amyloidosis. Int J Dermatol. 1987;26(2):135.PubMed

Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol. 1988;18(1 Pt 1):1–16.PubMed

Huilgol SC, Ramnarain N, Carrington P, et al. Cytokeratins in primary cutaneous amyloidosis. Australas J Dermatol. 1998;39(2):81–5.PubMed

Brownstein MH, Hashimoto K. Macular amyloidosis. Arch Dermatol. 1972;106(1):50–7.PubMed

Ramirez-Santos A, Labandeira J, Monteagudo B, Toribio J. Lichen amyloidosus without itching indicates that it is not secondary to chronic scratching. Acta Derm Venereol. 2006;86(6):561–2. doi:10.2340/00015555-0155.PubMed

Schreml S, Szeimies RM, Vogt T, et al. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. Eur J Dermatol. 2010;20(2):152–60. doi:10.1684/ejd.2010.0842.PubMed

Woollons A, Black MM. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol. 2001;145(1):105–9.PubMed

10.

Ollague W, Ollague J, Ferretti H. Epidemiology of primary cutaneous amyloidoses in South America. Clin Dermatol. 1990;8(2):25–9.PubMed

11.

McDonald RR, Georgouras KE. Skin disorders in Indo-Chinese immigrants. Med J Aust. 1992;157(4):288.PubMed

12.

Tan T. Epidemiology of primary cutaneous amyloidoses in southeast Asia. Clin Dermatol. 1990;8(2):20–4.PubMed

13.

Tanaka A, Arita K, Lai-Cheong JE, et al. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161(6):1217–24. doi:10.1111/j.1365-2133.2009.09311.x.PubMed

14.

Tey HL, Yosipovitch G. Itch in ethnic populations. Acta Derm Venereol. 2010;90(3):227–34. doi:10.2340/00015555-0867.PubMed

15.

Lin MW, Lee DD, Liu TT, et al. Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. Eur J Hum Genet. 2010;18(1):26–32. doi:10.1038/ejhg.2009.135.PubMed

16.

Hashimoto K, Ito K, Kumakiri M, Headington J. Nylon brush macular amyloidosis. Arch Dermatol. 1987;123(5):633–7.PubMed

17.

Macsween RM, Saihan EM. Nylon cloth macular amyloidosis. Clin Exp Dermatol. 1997;22(1):28–9.PubMed

18.

Somani VK, Hari S, Sita VN, Razvi F. Nylon friction dermatitis: a distinct subset of macular amyloidosis. Indian J Dermatol Venereol Leprol. 1995;61(3):145–7.PubMed

19.

Yoshida A, Takahashi K, Tagami H, Akasaka T. Lichen amyloidosis induced on the upper back by long-term friction with a nylon towel. J Dermatol. 2009;36(1):56–9. doi:10.1111/j.1346-8138.2008.00586.x.PubMed

20.

Venkataram MN, Bhushnurmath SR, Muirhead DE, Al-Suwaid AR. Frictional amyloidosis: a study of 10 cases. Australas J Dermatol. 2001;42(3):176–9.PubMed

21.

Verga U, Fugazzola L, Cambiaghi S, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol. 2003;59(2):156–61.

22.

Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol. 1992;27(6 Pt 2):S8–14.PubMed

23.

Atacan D, Ergin C, Celik G, et al. Oral isotretinoin: a new treatment alternative for generalized lichen amyloidosis. Australas J Dermatol. 2016;57(3):246–7. doi:10.1111/ajd.12316.PubMed

24.

Carlesimo M, Narcisi A, Orsini D, et al. A case of lichen amyloidosus treated with acitretin. Clin Ter. 2011;162(2):e59–61.PubMed

25.

Choi JY, Sippe J, Lee S. Acitretin for lichen amyloidosus. Australas J Dermatol. 2008;49(2):109–13. doi:10.1111/j.1440-0960.2008.00434.x.PubMed

26.

David M, Ingber A, Ben-Chetrit A, et al. Effect of etretinate on lichen amyloidosus. Dermatologica. 1987;175(6):302–3.PubMed

27.

Helander I, Hopsu-Havu VK. Treatment of lichen amyloidosus by etretinate. Clin Exp Dermatol. 1986;11(6):574–8.PubMed

28.

Marschalko M, Daroczy J, Soos G. Etretinate for the treatment of lichen amyloidosis. Arch Dermatol. 1988;124(5):657–9.PubMed

29.

Reider N, Sepp N, Fritsch P. Remission of lichen amyloidosus after treatment with acitretin. Dermatology. 1997;194(3):309–11.PubMed

30.

Tietze JK, Heppt MV, Flaig MJ, Thomas P. Successful treatment of lichen amyloidosus with oral alitretinoin. J Eur Acad Dermatol Venereol. 2016;30(5):884–5. doi:10.1111/jdv.13048.PubMed

31.

Aram H. Failure of etretinate (RO 10-9359) in lichen amyloidosus. Int J Dermatol. 1986;25(3):206.PubMed

32.

Hernandez-Nunez A, Dauden E, Moreno de Vega MJ, et al. Widespread biphasic amyloidosis: response to acitretin. Clin Exp Dermatol. 2001;26(3):256–9.PubMed

33.

Terao M, Nishida K, Murota H, Katayama I. Clinical effect of tocoretinate on lichen and macular amyloidosis. J Dermatol. 2011;38(2):179–84. doi:10.1111/j.1346-8138.2010.00962.x.PubMed

34.

Rados J, Marinovic Kulisic S, Lipozencic J, et al. Macular amyloidosis: a case report. Acta Dermatovenerol Croat. 2008;16(3):138–41.PubMed

35.

de Argila D, Ortiz-Romero PL, Ortiz-Frutos J, et al. Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. Clin Exp Dermatol. 1996;21(4):313–4.PubMed

36.

Parish JL. Topical vitamin D3 analogues: unapproved uses, dosages, or indications. Clin Dermatol. 2002;20(5):558–62.PubMed

37.

Khoo BP, Tay YK, Goh CL. Calcipotriol ointment vs. betamethasone 17-valerate ointment in the treatment of lichen amyloidosis. Int J Dermatol. 1999;38(7):539–41.PubMed

38.

Gupta R, Gupta S. Dexamethasone cyclophosphamide pulse therapy in lichen amyloidosus: a case report. J Dermatol Treat. 2007;18(4):249–51. doi:10.1080/09546630701271799.

39.

Tong PL, Walker WA, Glancy RJ, et al. Primary localized cutaneous nodular amyloidosis successfully treated with cyclophosphamide. Australas J Dermatol. 2013;54(1):e12–5. doi:10.1111/j.1440-0960.2011.00770.x.PubMed

40.

Das J, Gogoi RK. Treatment of primary localised cutaneous amyloidosis with cyclophosphamide. Indian J Dermatol Venereol Leprol. 2003;69(2):163–4.PubMed

41.

Jin AG, Por A, Wee LK, et al. Comparative study of phototherapy (UVB) vs. photochemotherapy (PUVA) vs. topical steroids in the treatment of primary cutaneous lichen amyloidosis. Photodermatol Photoimmunol Photomed. 2001;17(1):42–3.PubMed

42.

Behr FD, Levine N, Bangert J. Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine. Arch Dermatol. 2001;137(5):553–5.PubMed

43.

Cho TH, Lee MH. A case of lichen amyloidosus accompanied by vesicles and dyschromia. Clin Exp Dermatol. 2008;33(3):291–3. doi:10.1111/j.1365-2230.2007.02653.x.PubMed

44.

Teraki Y, Katsuta M, Shiohara T. Lichen amyloidosus associated with Kimura’s disease: successful treatment with cyclosporine. Dermatology. 2002;204(2):133–5. doi:10.1159/000051831.PubMed

45.

Kang MJ, Kim HS, Kim HO, Park YM. A case of atopic dermatitis-associated lichen amyloidosis successfully treated with oral cyclosporine and narrow band UVB therapy in succession. J Dermatol Treat. 2009;20(6):368–70. doi:10.3109/09546630802691325.

46.

Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs. 2005;65(6):827–58.PubMed

47.

Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology. 2002;205(4):420–1. doi:10.1159/000066426.PubMed

48.

Chakravarty K, Chanda M. Role of colchicine in primary localised cutaneous amyloidosis. Indian J Dermatol Venereol Leprol. 1995;61(5):268–9.PubMed

49.

Schattner A. Colchicine: expanding horizons. Postgrad Med J. 1991;67(785):223–6.PubMedPubMedCentral

50.

Capriotti K, Capriotti JA. Dimethyl sulfoxide: history, chemistry, and clinical utility in dermatology. J Clin Aesthet Dermatol. 2012;5(9):24–6.PubMedPubMedCentral

51.

Monfrecola G, Iandoli R, Bruno G, Martellotta D. Lichen amyloidosus: a new therapeutic approach. Acta Derm Venereol. 1985;65(5):453–5.PubMed

52.

Pravata G, Pinto G, Bosco M, et al. Unusual localization of lichen amyloidosus: topical treatment with dimethylsulfoxide. Acta Derm Venereol. 1989;69(3):259–60.PubMed

53.

Kobayashi T, Yamasaki Y, Watanabe T, Onoda N. Extensive lichen amyloidosus refractory to DMSO. J Dermatol. 1995;22(10):755–8.PubMed

54.

Ozkaya-Bayazit E, Kavak A, Gungor H, Ozarmagan G. Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol. 1998;37(12):949–54.PubMed

55.

Pandhi R, Kaur I, Kumar B. Lack of effect of dimethylsulphoxide in cutaneous amyloidosis. J Dermatol Treat. 2002;13(1):11–4. doi:10.1080/09546630252775180.

56.

Bautista DM, Wilson SR, Hoon MA. Why we scratch an itch: the molecules, cells and circuits of itch. Nat Neurosci. 2014;17(2):175–82. doi:10.1038/nn.3619.PubMedPubMedCentral

57.

Zeidler C, Metze D, Stander S. Successful treatment of lichen amyloidosis using capsaicin 8% patch. J Eur Acad Dermatol Venereol. 2016;30(7):1236–8. doi:10.1111/jdv.13165.PubMed

58.

Galeotti N, Di Cesare Mannelli L, Mazzanti G, et al. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322(3):145–8.PubMed

59.

Frolich M, Enk A, Diepgen TL, Weisshaar E. Successful treatment of therapy-resistant pruritus in lichen amyloidosis with menthol. Acta Derm Venereol. 2009;89(5):524–6. doi:10.2340/00015555-0725.PubMed

60.

Hallel-Halevy D, Finkelstein E, Grunwald MH, Halevy S. Lichen amyloidosus treated by hydrocolloid dressings. J Eur Acad Dermatol Venereol. 2004;18(6):691–2. doi:10.1111/j.1468-3083.2004.00940.x.PubMed

61.

Weyers W, Weyers I, Bonczkowitz M, et al. Lichen amyloidosus: a consequence of scratching. J Am Acad Dermatol. 1997;37(6):923–8.PubMed

62.

David M, Lowe NJ. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol. 1989;21(3 Pt 1):511–4.PubMed

63.

Yew YW, Tey HL. Itch in familial lichen amyloidosis: effective treatment with amitriptyline in two cases. Dermatol Ther. 2014;27(1):12–5. doi:10.1111/dth.12023.PubMed

64.

Gupta MA, Gupta AK. Antidepressant drugs in dermatology. Skin Ther Lett. 2001;6(8):3–5.

65.

Al Yahya RS. Treatment of primary cutaneous amyloidosis with laser: a review of the literature. Lasers Med Sci. 2016;31(5):1027–35. doi:10.1007/s10103-016-1917-8.PubMed

66.

Norisugi O, Yamakoshi T, Shimizu T. Successful treatment of lichen amyloidosis using a CO2 surgical laser. Dermatol Ther. 2014;27(2):71–3. doi:10.1111/dth.12057.PubMed

67.

Esmat SM, Fawzi MM, Gawdat HI, et al. Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: a randomized clinical trial. Lasers Surg Med. 2015;47(5):388–95. doi:10.1002/lsm.22361.PubMed

68.

Truhan AP, Garden JM, Roenigk HH Jr. Nodular primary localized cutaneous amyloidosis: immunohistochemical evaluation and treatment with the carbon dioxide laser. J Am Acad Dermatol. 1986;14(6):1058–62.PubMed

69.

Lesiak A, Rakowski A, Brzezinska A, et al. Effective treatment of nodular amyloidosis with carbon dioxide laser. J Cutan Med Surg. 2012;16(5):372–4.PubMed

70.

Kakani RS, Goldstein AE, Meisher I, Hoffman C. Nodular amyloidosis: case report and literature review. J Cutan Med Surg. 2001;5(2):101–4. doi:10.1007/s102270000014.PubMed

71.

Ritchie SA, Beachkofsky T, Schreml S, et al. Primary localized cutaneous nodular amyloidosis of the feet: a case report and review of the literature. Cutis. 2014;93(2):89–94.PubMed

72.

Panchaprateep R, Tusgate S, Munavalli GS, Noppakun N. Fractional 1,550 nm ytterbium/erbium fiber laser in the treatment of lichen amyloidosis: clinical and histological study. Lasers Surg Med. 2015;47(3):222–30. doi:10.1002/lsm.22338.PubMed

73.

Barsky M, Buka RL. Pulsed dye laser for the treatment of macular amyloidosis: a case report. Cutis. 2014;93(4):189–92.PubMed

74.

Sawamura D, Sato-Matsumura KC, Shibaki A, et al. A case of lichen amyloidosis treated with pulsed dye laser. J Eur Acad Dermatol Venereol. 2005;19(2):262–3. doi:10.1111/j.1468-3083.2005.01038.x.PubMed

75.

Alster TS, Manaloto RM. Nodular amyloidosis treated with a pulsed dye laser. Dermatol Surg. 1999;25(2):133–5.PubMed

76.

Anitha B, Mysore V. Lichen amyloidosis: novel treatment with fractional ablative 2,940 nm erbium:YAG laser treatment. J Cutan Aesthet Surg. 2012;5(2):141–3. doi:10.4103/0974-2077.99459.PubMedPubMedCentral

77.

Ostovari N, Mohtasham N, Oadras MS, Malekzad F. 532-nm and 1064-nm Q-switched Nd:YAG laser therapy for reduction of pigmentation in macular amyloidosis patches. J Eur Acad Dermatol Venereol. 2008;22(4):442–6. doi:10.1111/j.1468-3083.2007.02473.x.PubMed

78.

Liu HT. Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser. Dermatol Surg. 2000;26(10):958–62.PubMed

79.

Alonso-Gonzalez J, Rodriguez-Granados MT, Toribio J. Satisfactory response to narrowband UV-B therapy in generalized lichen amyloidosis. Actas Dermsifiliogr. 2013;104(6):527–9. doi:10.1016/j.ad.2012.07.014.

80.

Oiso N, Yudate T, Kawara S, Kawada A. Successful treatment of lichen amyloidosus associated with atopic dermatitis using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids and an antihistamine. Clin Exp Dermatol. 2009;34(8):e833–6. doi:10.1111/j.1365-2230.2009.03574.x.PubMed

81.

Parsi K, Kossard S. Thermosensitive lichen amyloidosis. Int J Dermatol. 2004;43(12):925–8. doi:10.1111/j.1365-4632.2004.02273.x.PubMed

82.

Kalkan G, Markoc F, Bas Y. An alternative treatment model: the combination therapy of narrow band ultraviolet B phototherapy and tacrolimus ointment 0.1% in biphasic amyloidosis. J Pak Med Assoc. 2014;64(5):579–82.PubMed

83.

Hudson LD. Macular amyloidosis: treatment with ultraviolet B. Cutis. 1986;38(1):61–2.PubMed

84.

Grimmer J, Weiss T, Weber L, et al. Successful treatment of lichen amyloidosis with combined bath PUVA photochemotherapy and oral acitretin. Clin Exp Dermatol. 2007;32(1):39–42. doi:10.1111/j.1365-2230.2006.02244.x.PubMed

85.

Tran D, Kwok YK, Goh CL. A retrospective review of PUVA therapy at the National Skin Centre of Singapore. Photodermatol Photoimmunol Photomed. 2001;17(4):164–7.PubMed

86.

Soler-Carrillo J, Alsina-Gibert MM, Mascaro JM. Lichen amyloidosus universalis associated with long-term drug intake. Dermatology. 1997;195(3):286–8.PubMed

87.

Engin B, Tufekci O, Yazici A, Ozdemir M. The effect of transcutaneous electrical nerve stimulation in the treatment of lichen simplex: a prospective study. Clin Exp Dermatol. 2009;34(3):324–8. doi:10.1111/j.1365-2230.2008.03086.x.PubMed

88.

Yuksek J, Sezer E, Aksu M, Erkokmaz U. Transcutaneous electrical nerve stimulation for reduction of pruritus in macular amyloidosis and lichen simplex. J Dermatol. 2011;38(6):546–52. doi:10.1111/j.1346-8138.2010.01081.x.PubMed

89.

Yong AS, Murphy JG, Shah N. Nodular localized cutaneous amyloidosis in an immunosuppressed patient. Int J Dermatol. 2015;54(6):708–9. doi:10.1111/ijd.12140.PubMed

90.

Fujisawa T, Shu E, Ikeda T, Seishima M. Primary localized cutaneous nodular amyloidosis that appeared in a patient with severe atopic dermatitis. J Dermatol. 2012;39(3):312–3. doi:10.1111/j.1346-8138.2011.01247.x.PubMed

91.

Lien MH, Railan D, Nelson BR. The efficacy of dermabrasion in the treatment of nodular amyloidosis. J Am Acad Dermatol. 1997;36(2 Pt 2):315–6.PubMed

92.

Okazaki M, Hisatomi T, Sarukawa S. Aesthetic upper lip reconstruction with vermilion submucosal-pedicle cross-lip flap. J Craniofacial Surg. 2006;17(6):1259–62. doi:10.1097/01.scs.0000246737.99718.87.

93.

Ueno M, Yamamoto T, Yamanaka M, Matsunaga T. Nodular amyloidosis in a patient with liver cirrhosis. Dermatol Online J. 2011;17(7):10.PubMed

94.

Vestey JP, Tidman MJ, McLaren KM. Primary nodular cutaneous amyloidosis: long-term follow-up and treatment. Clin Exp Dermatol. 1994;19(2):159–62.PubMed

95.

Aoki M, Kawana S. Lichen amyloidosis of the auricular concha: successful treatment with electrodesiccation. J Dermatol. 2009;36(2):116–7. doi:10.1111/j.1346-8138.2009.00603.x.PubMed

96.

Harahap M, Marwali MR. The treatment of lichen amyloidosis: a review and a new technique. Dermatol Surg. 1998;24(2):251–4.PubMed

97.

Savant SS. Therapeutic regional dermabrasion in papular lichen amyloidosis of shins. Indian J Dermatol Venereol Leprol. 1995;61(4):196–201.PubMed

98.

Mun KS, Pailoor J, Reddy SC. Primary localised deep cutaneous amyloidosis of the eyelid. Malays J Pathol. 2005;27(2):113–5.PubMed

99.

Santos-Briz A, Canueto J, Antunez P, et al. Primary cutaneous localized amyloid elastosis. Am J Dermatopathol. 2010;32(1):86–90. doi:10.1097/DAD.0b013e3181b1c62f.PubMed

100.

Sangen Y, Kawada A, Maeda A, et al. Primary localized cutaneous amyloidosis in association with papillary thyroid carcinoma. J Cutan Med Surg. 2002;6(4):332–4. doi:10.1007/s10227-001-0052-7.PubMed

101.

Schucht K, Schroder J, Siegmund H, et al. Nodular cutaneous amyloidosis at the temple. Case Rep Dermatol. 2016;8(2):193–6. doi:10.1159/000447234.PubMedPubMedCentral

102.

Haverkampf S, Evert K, Schroder J, Schreml S. Nodular cutaneous amyloidosis resembling a giant tumor. Case Rep Dermatol. 2016;8(1):22–5. doi:10.1159/000443950.PubMedPubMedCentral

103.

Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2):457–64. doi:10.1182/blood-2006-07-035352.PubMed

Titel: Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review
verfasst von: Till Weidner
Tanja Illing
Peter Elsner
Publikationsdatum: 01.10.2017
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 5/2017
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-017-0278-9

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Sunscreens: An Update

Comment on: “Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study”

Increasing Frequency of Seborrheic Keratosis Diagnoses as a Favorable Consequence of Teledermatology-Based Skin Cancer Screening: A Cross-sectional Study of 34,553 Patients

Comment on: “A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients”

Psoriasis, Depression, and Inflammatory Overlap: A Review